Managing Partner
Tamarind HillCheck size: $2M-$7M seed rounds, as published by Tamarind Hill.
Mark Shary invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.
Operator-led B2B healthcare teams with early product-market fit where Tamarind Hill's sector network and hands-on commercialization support can be decisive.
Generalist opportunities, consumer-only healthcare and companies without early product-market-fit evidence or a clear strategic-value fit are less aligned.
Show the B2B healthcare problem, early product-market-fit evidence, care-cost or supply-chain impact, commercialization plan and why Tamarind Hill can add strategic value.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Mark Shary is a current Managing Partner at Tamarind Hill, according to the firm's official roster. No additional personal background is inferred where the firm does not publish a biography.